US Patent

US9375405 — Rapid dissolution formulation of a calcium receptor-active compound

Formulation · Assigned to Amgen Inc · Expires 2026-09-22 · 0y remaining

Vulnerability score 60/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a pharmaceutical composition with a controlled dissolution profile containing a calcium receptor-active compound, such as cinacalcet hydrochloride.

USPTO Abstract

The present invention relates to a pharmaceutical composition comprising a therapeutically effective amount of a calcium receptor-active compound and at least one pharmaceutically acceptable excipient, wherein the composition has a controlled dissolution profile. The present invention further relates to a method of manufacturing the pharmaceutical composition, as well as a method of treating a disease using the pharmaceutical composition.

Drugs covered by this patent

Patent Metadata

Patent number
US9375405
Jurisdiction
US
Classification
Formulation
Expires
2026-09-22
Drug substance claim
No
Drug product claim
Yes
Assignee
Amgen Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.